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PURPOSE. Pseudoexfoliation (PEX) syndrome is a generalized
elastic microfibrillopathy characterized by fibrillar deposits in
intra- and extraocular tissues. Genetic and nongenetic factors
are known to be involved in its etiopathogenesis. This study
was focused on six functional candidate genes involved in PEX
material deposition and the analysis of their potential associa-
tion with PEX syndrome and PEX glaucoma (PEXG).
METHODS. Fifty single-nucleotide polymorphisms (SNPs) captur-
ing 95% of overall genetic variance observed in Europeans at
loci for FBN1, LTBP2, MFAP2, TGM2, TGF-b1, and CLU were
genotyped in 333 unrelated PEX-affected and 342 healthy in-
dividuals of German origin, and a genetic association study was
performed. To replicate the findings, two SNPs of the CLU
gene were genotyped in a further 328 unrelated German pa-
tients with PEX as well as in 209 Italian patients with PEX and
190 Italian control subjects.
RESULTS. Association with PEX was observed only for the SNP
rs2279590 in intron 8 of the CLU gene coding for clusterin
(corrected P  0.0347, OR  1.34) in our first German cohort.
Likewise, a frequent haplotype encompassing the associated
risk allele showed nominally significant association. None of
remaining SNPs or SNP haplotypes were associated with PEX.
The association found was confirmed in a second German
cohort (P 0.0244) but not in the Italian cohort (P 0.7173).
In addition, the association with CLU SNP rs2279590 was more
significant in German patients with PEX syndrome than in
those with PEXG.
CONCLUSIONS. Genetic variants in the gene encoding clusterin
may represent a risk factor for PEX in German patients but not
in Italian patients. Variants in FBN1, LTBP2, MFAP2, TGF-b1,
and TGM2 do not play a major role in the etiology of PEX
syndrome, at least in German patients. (Invest Ophthalmol Vis
Sci. 2009;50:2796–2801) DOI:10.1167/iovs.08-2339
Pseudoexfoliation (PEX) syndrome represents a commonage-related systemic disorder affecting approximately 10%
to 20% of the general population over age 60 and involving
both genetic and nongenetic factors in its etiopathogenesis.1,2
It is characterized by pathologic accumulation of an abnormal
fibrillar extracellular material in the anterior segment of the eye
and in various extraocular tissues.3 The characteristic PEX
fibrils appear to be multifocally produced by various intraocu-
lar cell types including the pre-equatorial lens epithelium, non-
pigmented ciliary epithelium, trabecular endothelium, corneal
endothelium, vascular endothelial cells, and virtually all cell
types of the iris.4 The gradual buildup of PEX material in the
trabecular meshwork most probably generates an increased
outflow resistance and correlates with the intraocular pressure
(IOP) level and the severity of glaucomatous optic nerve dam-
age.5,6 PEX syndrome in fact is currently the most important
single identifiable risk factor for open-angle glaucoma world-
wide.7 In some populations (e.g., Baltic, Mediterranean, and
Arabian), the frequency of PEX-associated secondary open-
angle glaucoma (PEXG) may reach a higher percentage than
the primary form of the disease (POAG). For instance, PEX
syndrome accounts for 77% of all cases of open-angle glaucoma
in the eastern region of the Arabian Peninsula.8
Variable presence of PEX in different populations and in-
creased risk of PEX in relatives of affected patients support a
genetic basis for PEX. Recently, strong genetic association with
single-nucleotide polymorphisms (SNPs) in the gene encoding
lysyl oxidase-like 1 (LOXL1) was reported in patients from
Iceland and Sweden.9 Subsequently, this association has been
widely replicated in other European and Asian populations,
including our own study group.10
Although the underlying pathophysiology has not yet been
elucidated, recent molecular biological evidence obtained
from differential gene expression analyses suggests that PEX
syndrome is an elastic microfibrillopathy associated with an
excessive production of elastic microfibril components, such
as fibrillin-1 (FBN1), microfibrillar-associated protein 2
(MFAP2), and latent transforming growth factor -binding pro-
teins (LTBPs), with enzymatic cross-linking processes involving
transglutaminase (TGM2), increased levels of transforming
growth factor (TGF-b1), and decreased levels of clusterin
(CLU), an extracellular chaperone, that may promote the ab-
normal aggregation and deposition of the fibrillar material.11,12
A recent proteomic approach confirmed the presence of elas-
tic fiber components and clusterin within PEX material depos-
its.13 Based on these findings, we evaluated, whether variations
in functional candidate genes encoding fibrillin 1 (FBN1), la-
tent transforming growth factor -binding protein 2 (LTBP2),
microfibrillar-associated protein 2 (MFAP2), transforming
growth factor beta 1 (TGF-b1), transglutaminase 2 (TGM2), and
clusterin (CLU) are associated with PEX syndrome and PEXG.
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TABLE 1. Phenotypic Composition, Age and Sex Distribution in Patients with PEX or PEXG or and Healthy Subjects
n PEX PEXG Mean Age  SD Min. Max. Female Male
German cohorts
Patients
Discovery 333 167 166 79.2  8.5 49 99 195 138
Replication 328 35 293 73.9  9.0 51 98 192 136
Control subjects 342 73.9  6.4 51 92 193 149
Italian cohorts
Patients 209 76 133 78.3  7.7 60 101 127 82
Control subjects 190 76.5  6.9 58 91 109 81
TABLE 2. Allele Frequencies of the 50 htSNPs in Patients and Control Subjects and Results of 2 Statistics
Gene/No. Name Allele Cases Controls 2 P Pc*
LTBP2
1 rs10149538 G 0.508 0.480 1.057 0.3040
2 rs2190876 A 0.461 0.434 0.989 0.3199
3 rs11621693 A 0.153 0.146 0.140 0.7081
4 rs10146812 A 0.721 0.670 4.160 0.0414 0.4222
5 rs1005154 C 0.394 0.349 2.899 0.0886
6 rs862046 C 0.597 0.519 7.928 0.0049 0.0733
7 rs2302114 G 0.580 0.519 5.081 0.0242 0.2837
8 rs699370 A 0.423 0.354 6.571 0.0104 0.1400
9 rs3815328 G 0.663 0.653 0.144 0.7047
10 rs862026 C 0.432 0.406 0.905 0.3414
11 rs12588574 G 0.795 0.769 1.287 0.2566
12 rs11159088 G 0.412 0.374 1.931 0.1646
13 rs7148764 T 0.524 0.497 0.938 0.3328
14 rs7150659 C 0.592 0.542 3.260 0.0710
15 rs4903242 T 0.541 0.519 0.633 0.4263
16 rs3784024 T 0.785 0.779 0.087 0.7685
17 rs7401961 G 0.636 0.617 0.499 0.4798
18 rs7150223 T 0.488 0.471 0.401 0.5264
19 rs8014087 C 0.541 0.526 0.288 0.5912
20 rs12435481 C 0.566 0.560 0.052 0.8197
21 rs8006778 T 0.495 0.465 1.246 0.2643
22 rs1866628 T 0.498 0.450 3.085 0.0790
23 rs989910 C 0.502 0.466 1.639 0.2004
24 rs11159094 A 0.479 0.447 1.341 0.2468
25 rs1077662 G 0.469 0.455 0.280 0.5964
26 rs888414 A 0.391 0.377 0.268 0.6050
27 rs12892228 T 0.472 0.468 0.027 0.8700
28 rs10047892 T 0.539 0.525 0.273 0.6015
29 rs11621186 T 0.524 0.509 0.293 0.5883
CLU
1 rs3087554 A 0.828 0.796 2.232 0.1352
2 rs2279590 A 0.417 0.347 6.882 0.0087 0.0347
3 rs9331931 C 0.748 0.719 1.386 0.2390
4 rs11136000 A 0.398 0.340 4.838 0.0278 0.0958
5 rs9331888 G 0.695 0.689 0.052 0.8204
FBN1
1 rs1042078 C 0.288 0.243 3.481 0.0621
2 rs2291117 C 0.122 0.119 0.026 0.8720
3 rs1807301 G 0.252 0.227 1.154 0.2827
MFAP2
1 rs6691985 C 0.721 0.673 3.315 0.0686
2 rs12097163 G 0.228 0.212 0.489 0.4842
3 rs3754511 T 0.811 0.796 0.452 0.5014
4 rs3738815 G 0.818 0.783 2.470 0.1160
5 rs2076604 A 0.821 0.783 3.140 0.0764
TGF-b1
1 rs8179181 T 0.272 0.259 0.293 0.5885
2 rs4803455 A 0.502 0.499 0.012 0.9119
3 rs1982072 T 0.311 0.306 0.035 0.8513
TGM2
1 rs6127200 C 0.161 0.158 0.024 0.8775
2 rs11696730 T 0.942 0.925 1.676 0.1954
3 rs6023527 G 0.161 0.119 4.771 0.0289 0.1329
4 rs4811529 G 0.150 0.118 2.926 0.0872
5 rs2235582 A 0.411 0.361 3.560 0.0592
* Pc value: P after permutation correction (n  10,000).
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METHODS
Study Populations
The study was approved by the ethics review boards of the Medical
Faculty of the University of Erlangen-Nuremberg (Germany) and that of
the hospital in Monfalcone-Gorizia (Italy) and was conducted in accor-
dance with the tenets of the Declaration of Helsinki. All subjects gave
informed consent before entering the study. The first group of patients
with PEX (discovery group) consisted of a total of 333, the replication
group of 328 subjects of German origin. All individuals underwent
standardized clinical examination for signs of PEX syndrome at the
Ophthalmology Department of the University of Erlangen-Nuremberg
and Wu¨rzburg. All patients with PEX had to have manifest PEX material
on the anterior capsule and/or pupillary margin in mydriasis by slit
lamp biomicroscopy. Secondary open-angle glaucoma due to PEX syn-
drome was defined, if elevated intraocular pressure (IOP 20 mm Hg),
an open chamber angle, characteristic visual field defects in computed
perimetry, and characteristic glaucomatous disc atrophy were found in
the presence of manifest PEX deposits on the anterior lens capsule
and/or pupillary margin. Age and sex distribution of the groups of
patients are shown in Table 1. Two hundred nine patients of Italian
origin were examined at the Ophthalmology Department of the Mon-
falcone Hospital (Italy) with identical clinical examinations.
A total of 342 healthy German subjects and 190 healthy Italian
subjects were recruited from the same geographic regions as the
patients. All control subjects underwent ophthalmic examination and
were matched for age and sex (Table 1). Overall, healthy individuals
had IOP levels below 20 mm Hg, no glaucomatous disc damage, no
PEX material deposits on anterior lens capsule and/or pupillary margin,
no clinical signs indicating early or suspect PEX (e.g., atrophy of the
iridal pigment epithelium at the pupillary margin, secondary melanin
dispersion in the chamber angle and anterior chamber after dilation of
the pupil, no dewlike condensation on the anterior lens capsule, normal
mydriasis) and no family history of PEX or glaucoma. Visual acuity was at
least 0.8 and the optic media were clear for ophthalmic examination.
DNA Extraction and Genotyping
Genomic DNAs were extracted from peripheral blood leukocytes of
patients with PEX and control individuals by using automated tech-
niques (Flex 3000; AutoGen Holliston, MA, using Flexigene chemistry;
Qiagen, Hilden, Germany). Fifty haplotype-tagging (ht)SNPs distributed
among the six candidate genes (29 in LTBP2, 5 in CLU, 5 in MFAP2, 5
in TGM2, 3 in FBN1, and 3 in TGF-b1) were selected capturing more
than 95% of genetic diversity in Europeans, based on the HapMap
CEPH (CEU) data (http://www.hapmap.org/). Genotyping of 40
htSNPs was performed with a genotyping system assay (SNPlex; Ap-
plied Biosystems [ABI], Foster City, CA). Reactions were prepared
according to the manufacturer’s protocol and analyzed on a DNA
analyzer (model 3730; ABI). Data were evaluated with gene mapping
software (GeneMapper Software ver. 4.0; ABI). Ten SNPs were geno-
typed with predeveloped assays (TaqMan; ABI). Reactions were pre-
pared according to the manufacturer’s instructions and analyzed on a
sequence-detection system (Prism 7900HT; ABI), using standard ther-
mal cycling conditions. Genotype data for four arbitrarily selected SNPs
was verified by direct sequencing of 24 randomly chosen samples. The
average genotyping rate was 98.5%. Hardy-Weinberg equilibrium for all
SNPs was confirmed in the control group with the program Haploview.14
Statistical Analysis
Association analysis used allele counts (2). The haplotype block struc-
ture and SNP haplotype association was performed with the program
Haploview which uses 2 statistics for assessing haplotype association
(version 4.0).14 P  0.05 was considered statistically significant. Ob-
tained P values were corrected for multiple testing by a permutation
test (10,000 permutations; Haploview 4.0).
RESULTS
Association analysis in the German discovery cohort (Table 1)
was performed with the 29 SNPs identified in LTBP2, 5 in
MFAP2, 5 in TGM2, 3 in FBN1, 3 in TGF-b1, and 5 in CLU.
Among all SNPs analyzed, only allele A of SNP rs2279590
located at intron 8 of CLU encoding for clusterin showed a
marked difference in allelic frequency between patients with
PEX and control subjects (P  0.0087; Table 2). This associa-
tion remained significant after correction for multiple testing
with permutation analysis (corrected P  0.0347, OR  1.34;
Table 2). Haplotypes constructed with the five CLU SNPs were
also examined. Of interest the most frequent haplotype encom-
passing the associated risk allele A of the SNP rs2279590 showed
nominally significant association with PEX (P  0.05, Fig. 1).
Recently, a strong association of variants in lysyl oxidase-
like 1 (LOXL1) in PEX and PEXG was reported.9 Therefore, we
compared the allele frequencies at CLU locus conditioned on
the presence of the identified LOXL1 common risk haplotype
G-G, which is composed of the major alleles G of the two
FIGURE 1. LD structure of the genomic region of CLU and derived
haplotypes with corresponding frequencies in our cohorts. Haploview
plot showing pair-wise LD based on genotypes of 333 patients and 342
controls. Dark diamonds: regions of high LD (D  0.8). The relative
chromosomal position of each SNP in relation to the genomic organi-
zation of the clusterin gene is given in the upper diagram. Bottom:
distribution of respective haplotypes between patients and controls.
Haplotype 1 carrying the associated risk allele at SNP 2 (rs2279590,
bold) shows nominally significant association.
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coding SNPs rs1048661 and rs3825942. We stratified our discov-
ery German cohort and control group for carriers and noncarriers
of the risk haplotype G-G (Table 3). Although we observed no
association of the subgroups of non G-G carriers, association to
allele A of CLU SNP rs2279590 in carriers of LOXL1 G-G
haplotype was significant (corrected P  0.0062, Table 3).
To replicate the observed association, we genotyped SNP
rs2279590 tagging the associated CLU haplotype, A-A-C-A-G
(Fig. 1), in the replication cohort of 328 German patients with
PEX (Table 1). When comparing this cohort with the ophthal-
mologically examined and age-matched control group, we
found a similar difference in allelic frequency between patients
with PEX and control subjects (P 0.0244). To more faithfully
assess the strength of the associated risk, we combined both
German PEX cohorts (Table 4). A significant association was
observed in all patients with PEX only for allele A of SNP
rs2279590 (P  0.0050, corrected P  0.0123). Of note, this
association was more significant in patients classified with PEX
syndrome than with PEXG. The associated risk, though, is
rather modest (OR  1.45, Table 4).
In addition, we genotyped SNP rs3087554 recently re-
ported by Burdon et al.15 as possibly being associated with PEX
syndrome in the Australian Blue Mountains Eye Study cohort.
This SNP was not associated with PEX in the German com-
bined cohort; however, after the subclassification allele A of
this SNP was nominally significant associated with PEX syn-
drome (Table 4). A second replication cohort of 209 patients
with PEX collected in Northern Italy was also genotyped for
both SNPs, rs2279590 and rs3087554, but showed no evidence
of association, either at single SNP or at haplotype levels
(Tables 4, 5).
In the combined German cohort (661 patients), though,
haplotype analysis of both SNPs, which are in complete linkage
disequilibrium (LD, D  1, Fig. 1), showed haplotype AA to be
overrepresented compared with the control group. This asso-
ciation results also more significant in patients with PEX syn-
drome than in patients with PEXG (Table 5).
DISCUSSION
One currently proposed pathogenic concept of PEX syndrome
describes the condition as a specific type of stress-induced
elastosis, an elastic microfibrillopathy, associated with the ex-
cessive production of elastic microfibrils and their aggregation
into mature PEX fibrils by a variety of potentially elastogenic
cells.16 Growth factors, particularly TGF-1, increased cellular
and oxidative stress, and an impaired cellular protection and
proteasome system appear to be key factors in its pathogene-
sis.17 Because of an imbalance between matrix metalloprotein-
ases and their inhibitors and extensive cross-linking processes
involved in fiber formation, the pathologic material is not
properly degraded but progressively accumulates in tissues
(e.g., trabecular meshwork), over time.18 This concept of a
generalized elastosis gained substantial support by a recently
published genetic study showing that polymorphisms in the
lysyl oxidase-like 1 (LOXL1) gene, which is involved in elastic
fiber formation and stabilization, are associated with PEX syn-
drome and PEX glaucoma.9
Five of the candidate genes analyzed in this study, FBN1,
LTBP2,MFAP2, TGM2, and TGF-b1, are related to extracellular
matrix metabolism and showed increased expression levels in
anterior segment tissues of patients with PEX compared with
ocular tissues of healthy individuals.12 Hence, we hypothesized
that genetic differences in these genes could underlie these
differential expression patterns and confer risk to PEX. How-
ever, this approach failed to find any association of PEX with
any of the single 45 examined SNPs or with the here from
derived haplotypes. In fact, no significant differences in allele
or haplotype distribution in these five candidate genes were
detected between patients with PEX and control individuals,
suggesting that genetic variants at these loci are not relevant in
the development of PEX syndrome, at least in German patients.
Nevertheless, our study identified an association between
an intronic SNP in CLU, rs2279590, with PEX syndrome. The
association was seen in both the discovery and replication
cohorts from Germany suggesting that genetic variation at this
TABLE 3. Association of CLU SNP rs2279590 Allele A with LOXL1 Common Risk Haplotype G-G, Composed of Both G Alleles of the Two
LOXL1 Coding SNPs rs1048661 and rs3825942
LOXL1
Haplotypes
Patients
(n)
Controls
(n) Case Control 2 P Pc* OR 95% CI
G-G carriers 307 254 0.420 0.338 7.757 0.0054 0.0062 1.416 1.1082–1.8103
Non-G-G carriers 26 88 0.385 0.374 0.021 0.8852 1.0000
* Pc, P after permutation correction (n  10,000).
TABLE 4. ORs of CLU SNPs rs2279590 and rs3087554 in PEX and PEXG from Germany and Italy
Study Population (n)
rs2279590 A rs3087554 A
Freq. OR (95% CI) P Pc Freq. OR (95% CI) P
Germany
Controls (342) 0.347 0.796
PEX combined (661) 0.412 1.32 (1.09–1.60) 0.0050 0.0123 0.828 1.23 (0.97–1.56) 0.0816
PEXG (459) 0.402 1.26 (1.03–1.55) 0.0260 0.817 1.14 (0.89–1.47) 0.2964
PEX (202) 0.435 1.45 (1.12–1.87) 0.0041 0.0110 0.853 1.49 (1.06–2.07) 0.0195
Italy
Controls (190) 0.429 0.832
PEX combined (209) 0.416 0.95 (0.72–1.26) 0.7173 0.841 1.07 (0.74–1.56) 0.7096
PEXG (133) 0.413 0.94 (0.68–1.29) 0.6920 0.831 0.99 (0.65–1.51) 0.9800
PEX (76) 0.421 0.97 (0.66–1.42) 0.8742 0.860 1.24 (0.73–2.12) 0.4219
* Pc, P after permutation correction (n  10,000).
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locus is indeed involved in the etiopathogenesis of PEX. In
contrast, no association was evident in the Italian study group.
Several factors such as population specific differences in dis-
ease susceptibility loci or insufficient statistical power could
explain this difference. Of note, the association in the German
cohorts was more prevalent in patients with PEX without
glaucoma than in patients with PEXG. This finding could be
interpreted as variants in CLU predisposing primarily to the
pathologic PEX process itself rather than to the glaucomatous
process. The risk conferred, though, is modest with an OR
around 1.5, as is typical for many disease susceptibility variants
identified in complex diseases.
Given the relative small effect size of the observed associa-
tion, though, it is still possible that our finding is due to a type
I error, despite the large sample size of our cohort. Thus, we
assessed the significance of our finding with 10,000 random
permutation tests. When correcting P values in this way, the
association at SNP rs2279590 remained significant, suggesting
that this is a true finding. Of interest, the association is only
seen in patients with PEX carrying the LOXL1-risk haplotype
G-G but not in the small group carrying other nonrisk haplo-
types. Whether this is an incidental finding or due to a true
(genetic) interaction of either genes or their products remains
to be determined. At present, there are no data available con-
cerning an interaction between clusterin and any other of the
candidate genes analyzed with LOXL1.
Previous studies demonstrated a significantly reduced ex-
pression of the extracellular chaperone clusterin in the ante-
rior segment of PEX eyes.11,12 In vitro, clusterin has been
found to inhibit the formation of insoluble amyloid fibrils
resulting from the aggregation of amyloid , apolipoprotein
C-II, and a variety of other fibril-forming peptides.19,20 Clus-
terin also has been reported to associate with soluble amyloid
 in plasma and cerebrospinal fluid, suggesting that the inter-
action may preclude amyloid  aggregation and fibrillization in
biological fluids.19,20 This observed deficiency in clusterin, a
highly efficient extracellular chaperone, may therefore pro-
mote the chronic, stable accumulation of PEX material, an
abnormal fibrillar extracellular matrix product, in anterior seg-
ment tissues of PEX eyes.
Clusterin gene expression appears to be responsive to a
variety of cytokines, growth factors, and stress-inducing agents
through many regulatory elements within the CLU promoter
region.21 Although it is very well possible that SNP rs2279590
is only in LD with another causative variant in CLU, we cannot
exclude that it itself has an effect on gene expression, which
led us to perform a bioinformatic analysis of intron 8 for
transcription factor binding sites (MatInspector software;
Genomatix, Munich, Germany).22 Of interest, this program
predicts a potential intronic vitamin D receptor responsive
element (VDRE) for the allele containing the major nonrisk
allele G of rs2279590. This hypothesis must be corroborated by
future functional studies, to provide conclusive evidence of its
potential causality. Similarly, investigations of this SNP in other
populations, especially in patients with PEX without glaucoma
are now needed to further strengthen the association of CLU
with PEX syndrome.
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